Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Founded
2017
Number of Employees
233
Website
http://www.allogene.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)